- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Myriad Genetics Inc. (MYGN)
by latest | most commented
-
Intuitive Surgical: Great Technology, Tough Environment
-
FDA Calendar Updates: Novo Nordisk, Eisai, Acura, King and Myriad Pharma
-
Markets Focus on Employment
-
How Far Myriad Has Fallen: Is Information Leaking out?
-
Closing Update for Wednesday, July 1
-
Wednesday Options Update: XLP, MYGN, NYX, ELN
-
And You Thought Friday Was Boring
-
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
-
Central Bankers Kick into Action
-
Myriad Genetics Spinoff Now in Place
-
Dollar Up, Commodities Down
-
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
-
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly
-
Epicept May Have Potential, But How Long Are Investors Willing to Wait?
-
Soft Housing Data Dampens Markets
-
Gene Patenting Will Hinder Biotechs and Drugmakers from Curing Maladies
-
Profit Taking in Financial Stocks
-
Why I'm Exiting Myriad Genetics
-
Rethinking Myriad After 'Those in the Know' Have Left
-
Citi and Bank of America Lead Market Lower
-
This Week's 20 'Babies with Bath Water' and 16 'Dogs with Fleas'
-
Uncertainty Over Bank Stress
-
Taking Profits on the Euphoria Stampede
-
Updated FDA, Clinical Trial Calendars: Myriad Pharma Announces Phase 1 Trial
-
Time to Build Long and Short Positions
-
Impact of Blowout Earnings in a Downward Trending Market
-
15 Long Ideas for Buying on Strength
-
Where Might Genentech Investors Redeploy $47B?
-
Who's Next in Medical Technology Consolidation?
-
IBB: Newfound Stability Lures Biotech Investors
-
71 Stocks Leading the Nasdaq Higher
-
Little Rays of Sunshine in the Markets
-
Biotechs Lead Markets Higher
-
Bullish Thesis for Biotech Remains Intact
-
Myriad's Monster Results
-
Wall Street Breakfast: Must-Know News
-
Myriad Genetics - A Diagnostics Heavy Hitter
-
Create Your Own Diagnostics ETF
-
Hedge Fund Portfolio Tracking: D.E. Shaw & Co (David E. Shaw), Q3 2008
-
2008 Stock Market: 51 Rays of Light
-
Fast Money Recap - Bullish on Biotech (1/5/09)